- Rychert M, Wilkins C. A critical analysis of the implementation of a legal regulated market for new psychoactive substances
(“legal highs”) in New Zealand. Int J Drug Policy. 2018;55:88-94. doi: 10.1016/j.drugpo.2018.02.014.
2. Grafinger KE, Bernhard W, Weinmann W. Scheduling of new psychoactive substance the Swiss way: a review and critical analysis. Sci Justice. 2019;59(4):459-66. doi: 10.1016/j.scijus.2019.03.005.
3. Peacock A, Bruno R, Gisev N, Degenhardt L, Hall W, Sedefov R, et al. New psychoactive substances: challenges for drug surveillance, control, and public health responses. Lancet. 2019;394(10209):1668-84. doi: 10.1016/s0140-6736(19)32231-7.
4. Simão AY, Antunes M, Cabral E, Oliveira P, Rosendo LM, Brinca AT, et al. An update on the implications of new psychoactive
substances in public health. Int J Environ Res Public Health. 2022;19(8):4869. doi: 10.3390/ijerph19084869.
5. Beydilli İ, Duyan M, Yılmaz F, Arslan ED, Korkmaz İ, Akçimen M, et al. Concomitant substance use increases the toxic effect of synthetic cannabinoid (bonsai): a prospective study. Acta Biomed. 2020;92(1):e2021006. doi: 10.23750/abm.v92i1.9989.
6. Potts AJ, Cano C, Thomas SHL, Hill SL. Synthetic cannabinoid receptor agonists: classification and
nomenclature. Clin Toxicol (Phila). 2020;58(2):82-98. doi: 10.1080/15563650.2019.1661425.
7. Costas-Insua C. Searching for New Cannabinoid CB1 Receptor-Interacting Proteins [thesis]. Spain, Madrid:
Universidad Complutense de Madrid; 2022.
8. Alves VL, Gonçalves JL, Aguiar J, Teixeira HM, Câmara JS. The synthetic cannabinoids phenomenon: from structure
to toxicological properties. A review. Crit Rev Toxicol. 2020;50(5):359-82. doi: 10.1080/10408444.2020.1762539.
9. Gonçalves JL, Alves VL, Aguiar J, Teixeira HM, Câmara JS. Synthetic cathinones: an evolving class of new psychoactive
substances. Crit Rev Toxicol. 2019;49(7):549-66. doi: 10.1080/10408444.2019.1679087.
10. Soares J, Costa VM, Bastos ML, Carvalho F, Capela JP. An updated review on synthetic cathinones. Arch Toxicol.
2021;95(9):2895-940. doi: 10.1007/s00204-021-03083-3.
11. Schifano F, Napoletano F, Arillotta D, Zangani C, Gilgar L, Guirguis A, et al. The clinical challenges of synthetic
cathinones. Br J Clin Pharmacol. 2020;86(3):410-9. doi: 10.1111/bcp.14132.
12. Farré M, Papaseit E, Fonseca F, Torrens M. Addiction of hallucinogens, dissociatives, designer drugs and “legal highs”:
update on potential therapeutic use. In: el-Guebaly N, Carrà G, Galanter M, Baldacchino AM, eds. Textbook of Addiction
Treatment: International Perspectives. Cham: Springer; 2021. p. 259-79. doi: 10.1007/978-3-030-36391-8_19.
13. Simonato P. Evaluating and Expanding Knowledge and Awareness of Health Professionals on the Consumption and Adverse Consequences of Novel Psychoactive Substances (NPS) Through Innovative Information Technologic Tools
[dissertation]. University of Hertfordshire; 2015. doi: 10.18745/th.16557.
14. Cocchi V, Gasperini S, Hrelia P, Tirri M, Marti M, Lenzi M. Novel psychoactive phenethylamines: impact on genetic
material. Int J Mol Sci. 2020;21(24):9616. doi: 10.3390/ijms21249616.
15. Zashidova GA. New psychoactive substances (NPS) and problems associated with their use in the world and in
Uzbekistan. In: Drug Cultures and Policy in Germany, Central Asia and China. Nomos Verlagsgesellschaft mbH & Co. KG;
2022. p. 69-92.
16. Göl E, Çok I. New psychoactive substances in Turkey: narcotics cases assessed by the Council of Forensic Medicine between 2016 and 2017 in Ankara, Turkey. Forensic Sci Int. 2019;294:113-23. doi: 10.1016/j.forsciint.2018.11.003.
17. Varì MR, Pichini S, Giorgetti R, Busardò FP. New psychoactive substances—synthetic stimulants. WIRES Forensic Sci.
2019;1(2):e1197. doi: 10.1002/wfs2.1197.
18. Martins D, Garrido EM, Borges F, Garrido JM. Voltammetric profiling of new psychoactive substances: piperazine
derivatives. J Electroanal Chem (Lausanne). 2021;883:115054. doi: 10.1016/j.jelechem.2021.115054.
19. Nthiga JN. An Investigation on and Isolation of Parasites That Infect Humans Associated with Catha Edulis Leaves Sold in
Selected Parts of Nairobi County, Kenya [dissertation]. Jomo Kenyatta University of Agriculture and Technology (JKUAT); 2022.
20. Smith PR, Morley SR. New psychoactive substances. In: Rutty GN, ed. Essentials of Autopsy Practice: Reviews, Updates, and Advances. Cham: Springer; 2017. p. 59-85. doi: 10.1007/978-3-319-46997-3_4.
21. Simão AY, Antunes M, Cabral E, Oliveira P, Rosendo LM, Brinca AT, et al. An update on the implications of new psychoactive substances in public health. Int J Environ Res Public Health. 2022;19(8):4869. doi: 10.3390/ijerph19084869.
22. Corkery JM, Orsolini L, Papanti D, Schifano F, Miolo G, Stair JL, et al. Novel psychoactive substances (NPS) and
recent scenarios: epidemiological, anthropological and clinical pharmacological issues. In: Zloh M, Stair JL, Miolo G, eds. Light in Forensic Science: Issues and Applications. London: Royal Society of Chemistry; 2018. p. 207-557. doi:10.1039/9781788010344-00207.
23. Atumeyi AU, Ligom TT, Tivkaa JT. Intake and abuse of psychoactive substances and its relative consequences: a
review. Sci J Anal Chem. 2021;9(2):39-49. doi: 10.11648/j.sjac.20210902.12.
24. Ban TA. The role of serendipity in drug discovery. Dialogues Clin Neurosci. 2006;8(3):335-44. doi: 10.31887/DCNS.2006.8.3/tban.
25. Miyachi T, Ozaki A, Saito H, Sawano T, Tanimoto T, Crump A. Opioids: a ‘crisis’ of too much or not enough - or simply how
rich you are and where you live? Eur J Pain. 2021;25(6):1181-94. doi: 10.1002/ejp.1767.
26. Braunstein MM. Mindful Marijuana Smoking: Health Tips for Cannabis Smokers. Rowman & Littlefield; 2022.
27. Nosseir O, Hadad C. Chemical Warfare Agents and Treatments. American Chemical Society; 2021.
28. Bishop-Freeman SC, Young KA, Aurelius MB, Hudson JS. Pediatric opioid fatalities: what can we learn for prevention?
J Forensic Sci. 2021;66(4):1410-9. doi: 10.1111/1556-4029.14725.
29. Mazzoni IE. Contamination of sports supplements with novel psychoactive substances: an old history with new players. In:
Rabin O, Corazza O, eds. Emerging Drugs in Sport. Cham: Springer; 2022. p. 17-32. doi: 10.1007/978-3-030-79293-0_2.
30. McClure-Begley TD, Roth BL. The promises and perils of psychedelic pharmacology for psychiatry. Nat Rev Drug
Discov. 2022;21(6):463-73. doi: 10.1038/s41573-022-00421-7.
31. Ujváry I, Christie R, Evans-Brown M, Gallegos A, Jorge R, de Morais J, et al. DARK classics in chemical neuroscience:
etonitazene and related benzimidazoles. ACS Chem Neurosci. 2021;12(7):1072-92. doi: 10.1021/acschemneuro.1c00037.
32. Sanabria E, Cuenca RE, Esteso M, Maldonado M. Benzodiazepines: their use either as essential medicines or as toxics substances. Toxics. 2021;9(2):25. doi: 10.3390/toxics9020025.
33. Rinaldi R, Bersani G, Marinelli E, Zaami S. The rise of new psychoactive substances and psychiatric implications: a
wide-ranging, multifaceted challenge that needs far-reaching common legislative strategies. Hum Psychopharmacol.
2020;35(3):e2727. doi: 10.1002/hup.2727.
34. Yeh HT, Chen HY, Liu SW, Weng TI, Fang CC, Yu JH, et al. Clinical presentations and predictors of in-hospital mortality
in illicit drug users in the new psychoactive substances (NPS) endemic era in Taiwan. Toxics. 2022;10(7):386. doi:10.3390/toxics10070386.
35. Abdulrahim D, Bowden-Jones O. Textbook of Clinical Management of Club Drugs and Novel Psychoactive Substances: NEPTUNE Clinical Guidance. Cambridge University Press; 2022.
36. Varì MR, Mannocchi G, Tittarelli R, Campanozzi LL, Nittari G, Feola A, et al. New psychoactive substances: evolution in
the exchange of information and innovative legal responses in the European Union. Int J Environ Res Public Health.
2020;17(22):8704. doi: 10.3390/ijerph17228704.
37. James SP, Bondugji D. Gamma-Aminobutyric Acid (GABA) and the Endocannabinoids: Understanding the Risks and
Opportunities. In: El-Shemy HA, ed. Natural Drugs from Plants. IntechOpen; 2021. doi: 10.5772/intechopen.99242.
38. World Health Organization (WHO). WHO Expert Committee on Drug Dependence: Forty-Fourth Report. WHO; 2022.
39. Vincenti F, Gregori A, Flammini M, Di Rosa F, Salomone A. Seizures of new psychoactive substances on the Italian
territory during the COVID-19 pandemic. Forensic Sci Int. 2021;326:110904. doi: 10.1016/j.forsciint.2021.110904.
40. Orsolini L, Chiappini S, Corkery JM, Guirguis A, Papanti D, Schifano F. The use of new psychoactive substances (NPS)
in young people and their role in mental health care: a systematic review. Expert Rev Neurother. 2019;19(12):1253-64. doi: 10.1080/14737175.2019.1666712.
41. Smith SW, Garlich FM. Availability and supply of novel psychoactive substances. In: Dargan PI, Wood DM, eds.
Novel Psychoactive Substances. Boston: Academic Press; 2013. p. 55-77. doi: 10.1016/b978-0-12-415816-0.00003-1.
)